Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Autoimmune Disorders

Free Subscription Articles published in Lancet Retrieve available abstracts of 29 articles: HTML format

Single Articles

August 2022
1. RIDKER PM
   Autoimmune diseases and atherothrombotic risk.
   Lancet. 2022 Aug 26. pii: S0140-6736(22)01602.
   PubMed    
   
   
   
2. CONRAD N, Verbeke G, Molenberghs G, Goetschalckx L, et al
   Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.
   Lancet. 2022 Aug 26. pii: S0140-6736(22)01349.
   PubMed     Abstract available
   
   
   May 2022
3. RUPERTO N, Brunner HI, Posner HB, Lazariciu I, et al
   Tofacitinib for juvenile idiopathic arthritis - Authors' reply.
   Lancet. 2022;399:1866.
   PubMed    
   
   
   
4. MURRAY GM, Renton WD
   Tofacitinib for juvenile idiopathic arthritis.
   Lancet. 2022;399:1865-1866.
   PubMed    
   
   
   April 2022
5. SETHI S, De Vriese AS, Fervenza FC
   Acute glomerulonephritis.
   Lancet. 2022;399:1646-1663.
   PubMed     Abstract available
   
   
   
6. PRASAD A
   Angela Migowa: advocating for children with rheumatic diseases.
   Lancet. 2022;399:1294.
   PubMed    
   
   
   March 2022
7. YAKOVENKO V, Brauner R, Votinov E, Goldfarb Y, et al
   Infective endocarditis and thromboses due to antiphospholipid syndrome following acute Q fever.
   Lancet. 2022;399:1154.
   PubMed    
   
   
   January 2022
8. KAMOI K, Uchimaru K, Tojo A, Watanabe T, et al
   HTLV-1 uveitis and Graves' disease presenting with sudden onset of blurred vision.
   Lancet. 2022;399:60.
   PubMed    
   
   
   November 2021
9. CLARKE SLN, Ramanan AV
   Tofacitinib in juvenile idiopathic arthritis.
   Lancet. 2021;398:1943-1945.
   PubMed    
   
   
   
10. RUPERTO N, Brunner HI, Synoverska O, Ting TV, et al
    Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
    Lancet. 2021;398:1984-1996.
    PubMed     Abstract available
    
    
    
11. LODGE FM, Moody WE, Tosounidou S, Chue CD, et al
    Hydroxychloroquine-induced cardiomyopathy accelerated after gastric banding.
    Lancet. 2021;398:1913.
    PubMed    
    
    
    
12. BHUTTA ZA, Salam RA, Gomber A, Lewis-Watts L, et al
    A century past the discovery of insulin: global progress and challenges for type 1 diabetes among children and adolescents in low-income and middle-income countries.
    Lancet. 2021;398:1837-1850.
    PubMed     Abstract available
    
    
    
13. HELLER SR, Durrant A, Tandon N
    Insulin, the patient, and the health professional.
    Lancet. 2021;398:1785-1786.
    PubMed    
    
    
    
14. THE LANCET
    100 years of insulin: a technical success but an access failure.
    Lancet. 2021;398:1777.
    PubMed    
    
    
    
15. DEVI S
    Cold comfort: getting insulin to those who need it.
    Lancet. 2021;398:1791.
    PubMed    
    
    
    October 2021
16. CHEN LYC, Slack GW, Carruthers MN
    IgG4-related disease and Rosai-Dorfman-Destombes disease.
    Lancet. 2021;398:1213-1214.
    PubMed    
    
    
    
17. EMILE JF, Vaglio A, Cohen-Aubart F, Haroche J, et al
    IgG4-related disease and Rosai-Dorfman-Destombes disease - Authors' reply.
    Lancet. 2021;398:1214-1215.
    PubMed    
    
    
    August 2021
18. PERRY RJ, Tamborska A, Singh B, Craven B, et al
    Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01608.
    PubMed     Abstract available
    
    
    July 2021
19. RAMSPOTT JP, Neureiter D, Emmanuel K, Jager T, et al
    Granulomatosis with polyangiitis presents with skip lesions of the bowel.
    Lancet. 2021;398:e8.
    PubMed    
    
    
    
20. HAWKINS P, Chawke L, Cormican L, Wikenheiser-Brokamp KA, et al
    Autoimmune pulmonary alveolar proteinosis: a discrepancy between symptoms and CT findings.
    Lancet. 2021;398:e7.
    PubMed    
    
    
    June 2021
21. MCGINLEY MP, Cohen JA
    Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
    Lancet. 2021 Jun 24. pii: S0140-6736(21)00244.
    PubMed     Abstract available
    
    
    
22. NORGAARD K, Schmidt S
    Is reimbursement for alerts and real-time continuous glucose monitoring needed?
    Lancet. 2021;397:2230-2232.
    PubMed    
    
    
    
23. TSAGKAS C, Schafer S, Baumgartner A, Muller J, et al
    Syndrome of inappropriate antidiuretic hormone secretion and hypothalamic hypocortisolism in neuromyelitis optica.
    Lancet. 2021;397:2194.
    PubMed    
    
    
    
24. VISSER MM, Charleer S, Fieuws S, De Block C, et al
    Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial.
    Lancet. 2021 Jun 1. pii: S0140-6736(21)00789.
    PubMed     Abstract available
    
    
    May 2021
25. ROVIN BH, Teng YKO, Ginzler EM, Arriens C, et al
    Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Lancet. 2021 May 7. pii: S0140-6736(21)00578.
    PubMed     Abstract available
    
    
    
26. MOK CC
    A new old treatment for lupus nephritis.
    Lancet. 2021 May 7. pii: S0140-6736(21)00663.
    PubMed    
    
    
    April 2021
27. BAYAS A, Menacher M, Christ M, Behrens L, et al
    Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination.
    Lancet. 2021 Apr 14. pii: S0140-6736(21)00872.
    PubMed    
    
    
    
28. MIZELLE RM JR
    Diabetes, race, and amputations.
    Lancet. 2021;397:1256-1257.
    PubMed    
    
    
    October 2020
29. HABIB SM, Vermeer MH
    A baby with red plaques on the face and a first-degree heart block: neonatal lupus.
    Lancet. 2020;396:1432.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: